May 2026
📣 VC round data is live. Check it out!
Largest BioTech Public Companies in Brazil
Benchmark revenue and EBITDA valuation multiples for public comps like
Hypera, Establishment Labs, Diagnósticos da América, Blau Farmacêutica and Ourofino.
 | Hypera SA is a specialty and generic drug manufacturing company. The company has a focus on the pharmaceutical segments of the Brazilian market, along with a presence in nonprescription drugs and branded generics. Hypermarcas also possesses a share of generic medicines and prescription products. The company also has a wide sales and distribution structure. The Company's operating segments are Consumer Health, Branded Prescription, Similars e Generics, Skincare and the Non-Retail Market. | $4 | -16% | $3B | $4B | 2.8x | 9.6x | ||
| Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others. | $68 | +60% | $2B | $2B | 10.4x | (155.3x) | ||
| Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia). | $1 | +144% | $769M | $2B | 0.9x | 5.0x | ||
| Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs. | $2 | +11% | $522M | $526M | 1.6x | 5.0x | ||
| Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others. | $6 | +31% | $327M | $352M | 1.4x | 6.1x | ||
| Biomm SA is engaged in biotechnological processes for the production of active pharmaceutical ingredients and other industrial purposes, such as enzymes used in the production of Biofuels.The Company is patented for insulin production.The company develops processes for the production of insulin and other biotech products, as well as processes for other industrial applications, such as enzymes that are used in the production of biofuels. | $1 | +1% | $194M | $208M | 3.9x | 83.3x | ||
| Median | $3 | +21% | $645M | $1B | 2.2x | 5.6x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.